MDGL · Madrigal Pharmaceuticals, Inc.

Summary

Madrigal Pharmaceuticals reclassified two directors to balance board classes, with no impact on tenure or committee assignments.

Key takeaways

• Julian C. Baker and Daniel J. Brennan reclassified from Class III/II to Class I directors effective April 22, 2026.
• Reclassification aims to equalize board class sizes after the 2026 Annual Meeting.
• No changes to committee assignments or continuity of service for either director.
• Baker, Brennan, and James Daly nominated for re-election at the 2026 Annual Meeting.